Table 1 Baseline and disease characteristics of patients

From: A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer

 

Patients (n = 81)

Median age, years (range)

51 (26–75)

<55

49 (60%)

≥55

32 (40%)

Menopausal status

Pre- or perimenopausal

43 (53%)

Postmenopausal

38 (47%)

Stage at baseline

IIA

26 (32%)

IIB

26 (32%)

III

29 (36%)

Nodal status

N0

26 (32%)

N1

30 (37%)

N2

21 (26%)

N3

4 (5%)

Tumor size

T1

4 (5%)

T2

70 (86%)

T3-4

7 (9%)

 ER expression, mean (SD), %

78% (18)

 PR expression, mean (SD), %

49% (31)

 Ki67 level at baseline, mean (SD), %

40% (20)

HER2 status

IHC 2+/FISH+

25 (31%)

IHC 3+

56 (69%)

  1. Data are n (%) or mean (SD).
  2. SD standard deviation, ER estrogen receptor, PR progesterone receptor.
  3. IHC, immunohistochemistry, FISH, Fluorescence in situ hybridization.
Back to article page